Thyromimetics for the Treatment of Fatty Liver Diseases

a technology of fatty liver disease and thyromimetics, which is applied in the field of thyromimetics, can solve the problems of limiting the rate of fatty acid oxidation, affecting the effect of beneficial or detrimental effects, etc., and achieve the effects of reducing the fat content in the liver, preventing, treating or ameliorating fatty liver disease, and modulating gene expression

Inactive Publication Date: 2009-09-17
METABASIS THERAPEUTICS INC
View PDF2 Cites 34 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0052]The present invention relates to the use of thyromimetic compounds in methods of decreasing fat content in the liver of an animal comprising administering to said animal a therapeutically effective amount of a thyromimetic compound, a pharmaceutically acceptable salt thereof, or prodrugs thereof or pharmaceutically acceptable salts of said prodrugs. The invention further relates to methods of preventing, treating, or ameliorating fatty liver disease in an animal comprising administering to said animal a therapeutically effective amount of a thyromimetic compound, a pharmaceutically acceptable salt thereof, or prodrugs thereof or pharmaceutically acceptable salts of said prodrugs. The thyromimetic compounds bind to thyroid receptors in the l...

Problems solved by technology

Many of these products have biological activity suggesting that modulation of their levels m...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Thyromimetics for the Treatment of Fatty Liver Diseases
  • Thyromimetics for the Treatment of Fatty Liver Diseases
  • Thyromimetics for the Treatment of Fatty Liver Diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0959]Examples of the method of the invention includes the following. It will be understood that these examples are exemplary and that the method of the invention is not limited solely to these examples.

[0960]For the purposes of clarity and brevity compounds are referred to by compound numbers (from the Table below) in the biological examples below.

CompoundStructureNumber17 7 6cis-13-1TRIAC18

example a

Chronic Exposure to Thyroid Receptor Agonists in Normal Rats

[0961]The purpose of these studies was to compare the difference in efficacy to clear liver triglyceride content between T3 and various T3 mimetics that are carboxylic acids and T3 mimetics that are phosphonic acids. In one example, T3 and Compounds 7 and 17, which differ only in that for Compound 7, the X moiety of Formula II is —P(O)OH2 and for Compound 17, X is —C(O)OH, were compared. In the same example TRIAC and Compound 6, which differ only in that for Compound 6, X is —P(O)OH2 and for TRIAC, X is —C(O)OH, were compared. Efficacy was measured by analyzing total liver triglycerides.

[0962]Methods: Normal rats (Sprague-Dawley) were maintained on a standard diet. Compounds 7, 17, 6, TRIAC or T3 were administered by continuous infusion using an osmotic pump (Alzet; subcutaneous implant) at a dose of 1 mg / kg / day. The compounds were dissolved in 0.1N NaOH solution and the pH adjusted to 7.4-8.0. The compounds were brought up...

example b

Chronic Exposure to Thyroid Receptor Agonists in ob / ob Mice

[0966]The purpose of these studies was to compare the difference in efficacy to clear liver triglyceride content between Compound cis-13-1 and T3 in ob / ob mice.

[0967]Methods: ob / ob mice were maintained on a standard diet. Compound cis-13-1 was administered at doses of 3, 10 and 30 mg / kg / d orally in a CMC suspension. T3, 100 nmole / kg / d, was administered as an aqueous solution subcutaneously. Liver triglycerides were analyzed as described in example A. Epididymal fat pads were removed and weighed. Clinical chemistry analysis was performed by LabCorp (San Diego, Calif.).

[0968]Results: T3 did not significantly decrease liver triglyceride content (FIG. 1). However, Compound cis-13-1 decreased hepatic triglyceride content at 10 and 30 mg / kg / d (FIG. 1). Compound cis-13-1 did not decrease epididymal fat pad (EFP) weight. T3 significantly decreased EFP weight, consistent with a well described effect of T3 on lipolysis. Treatment of o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Molar densityaaaaaaaaaa
Dimensionless propertyaaaaaaaaaa
Login to view more

Abstract

The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit, under 35 U.S.C. § 119(e), of the earlier filing date of U.S. Provisional Application No. 60 / 684,572, filed May 26, 2005, the contents of which is incorporated by reference herein in its entirety, including figures.FIELD OF THE INVENTION[0002]The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.BACKGROUND OF THE INVENTION[0003]The following description of the background is provided to aid in understanding, but is not admitted to be, or to describe, prior art. All publications and their cited references are incorporated by reference in their entirety.[0004]Thyroid hormones (TH) are synthesized in the thyroid in response to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/70A61K31/19A61K31/662A61K31/675A61K9/48A61P1/16
CPCA61K31/192A61K31/661A61K31/662A61K31/665A61K31/683A61P1/16A61P3/00A61P3/04A61P3/06A61P5/14A61P43/00
Inventor CABLE, EDWARD E.ERION, MARK D.
Owner METABASIS THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap